Guaifenesin / potassium guaiacolsulfonate Pregnancy and Breastfeeding Warnings
Guaifenesin / potassium guaiacolsulfonate is also known as: Allfen, Cypex-LA, Humibid LA
Guaifenesin / potassium guaiacolsulfonate Pregnancy Warnings
Guaifenesin-potassium guaiacolsulfonate has been assigned to pregnancy category C by the FDA. Animal studies have not been reported. There are no controlled data in human pregnancy. Guaifenesin-potassium guaiacolsulfonate is only recommended for use during pregnancy when benefit outweighs risk.
Guaifenesin / potassium guaiacolsulfonate Breastfeeding Warnings
There are no data on the excretion of guaifenesin-potassium guaiacolsulfonate into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
References for pregnancy information
- "Product Information. Humibid L.A. (guaifenesin-potassium guaiacolsulfonate)." Carolina Pharmaceuticals Inc (2004):
References for breastfeeding information
- "Product Information. Humibid L.A. (guaifenesin-potassium guaiacolsulfonate)." Carolina Pharmaceuticals Inc (2004):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.